Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

ULTRASOUND ASSESSMENT OF GASTRİC VOLUME IN PREGNANT WOMEN UNDERGOİNG ELECTİVE CESAREAN SECTİON, WITH AND WITHOUT GESTATİONAL DIABETES MELLITUS (GDM)

8 de septiembre de 2026 actualizado por: Mehmet Tunç, Gaziantep City Hospital

THE PRIMARY OBJECTIVE OF THIS STUDY IS TO COMPARE GASTRIC VOLUME PRIOR TO ELECTIVE CESAREAN SECTION BETWEEN PREGNANT WOMEN DIAGNOSED WITH GESTATIONAL DIABETES MELLITUS (GDM) AND THOSE WITHOUT GDM.

THE SECONDARY OBJECTIVES ARE TO EVALUATE THE EFFECT OF GDM ON PREOPERATIVE RESIDUAL GASTRIC VOLUME AND TO OBTAIN DATA THAT COULD CONTRIBUTE TO CLINICAL ANESTHESIA PRACTICES REGARDING THE RISK OF ASPIRATION.

THIS STUDY AIMS TO OBTAIN OBJECTIVE ULTRASONOGRAPHIC DATA REGARDING THE ADEQUACY OF STANDARD FASTING PERIODS IN PREGNANT WOMEN, PARTICULARLY IN THE PRESENCE OF GDM.

Descripción general del estudio

Descripción detallada

DURING PREGNANCY, GASTRIC EMPTYING CAN BE AFFECTED AND THE RISK OF ASPIRATION MAY INCREASE DUE TO PHYSIOLOGICAL HORMONAL CHANGES, ELEVATED INTRA-ABDOMINAL PRESSURE, AND SLOWED GASTROINTESTINAL MOTILITY. ALTHOUGH CESAREAN SECTIONS ARE OFTEN PERFORMED UNDER REGIONAL ANESTHESIA, THEY REMAIN CLINICALLY RELEVANT IN TERMS OF ASPIRATION RISK DUE TO THE POTENTIAL NEED FOR GENERAL ANESTHESIA (1, 2).

GESTATIONAL DIABETES MELLITUS (GDM) IS A COMMON METABOLIC DISORDER DURING PREGNANCY THAT MAY AFFECT AUTONOMIC NERVOUS SYSTEM FUNCTION AND GASTROINTESTINAL MOTILITY. WHILE DIABETIC GASTROPARESIS IS WELL CHARACTERIZED IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS, DATA REGARDING THE EFFECT OF GDM ON GASTRIC EMPTYING DYNAMICS REMAIN LIMITED (2, 3).

IN RECENT YEARS, GASTRIC ULTRASONOGRAPHY HAS BECOME AN INCREASINGLY UTILIZED METHOD IN ANESTHESIA PRACTICE, ENABLING THE NON-INVASIVE ASSESSMENT OF GASTRIC CONTENTS AND VOLUME. THIS TECHNIQUE ALLOWS FOR THE OBJECTIVE EVALUATION OF GASTRIC CONTENTS REGARDLESS OF STANDARD FASTING INTERVALS AND FACILITATES AN INDIVIDUALIZED ASSESSMENT OF ASPIRATION RISK (3).

THE RATIONALE FOR THIS STUDY IS TO DETERMINE THE EFFECT OF GDM ON PREOPERATIVE GASTRIC VOLUME BY COMPARING GASTRIC VOLUMES MEASURED VIA GASTRIC ULTRASOUND IN PREGNANT WOMEN SCHEDULED FOR ELECTIVE CESAREAN SECTIONS, WITH AND WITHOUT A DIAGNOSIS OF GDM, THEREBY CONTRIBUTING TO PERIOPERATIVE ANESTHETIC RISK ASSESSMENT.

THIS STUDY HAS BEEN DESIGNED AS A PROSPECTIVE, OBSERVATIONAL, COMPARATIVE, AND PARALLEL-GROUP CLINICAL TRIAL

**PATIENT SELECTION:** PREGNANT WOMEN TO BE INCLUDED IN THE STUDY WILL BE SELECTED VIA A CONSECUTIVE SAMPLING METHOD (BASED ON THE ORDER OF ARRIVAL) FROM AMONG PATIENTS SCHEDULED FOR ELECTIVE CESAREAN SECTION AT GAZIANTEP CITY HOSPITAL BY THE DEPARTMENT OF ANESTHESIOLOGY AND REANIMATION AND THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, WHO MEET THE INCLUSION AND EXCLUSION CRITERIA.

PATIENTS WILL BE GROUPED SOLELY BASED ON THE PRESENCE OR ABSENCE OF GESTATIONAL DIABETES MELLITUS (GDM). NO SELECTIVE SAMPLING WILL BE PERFORMED REGARDING AGE, BODY MASS INDEX, OBSTETRIC CHARACTERISTICS, SURGICAL TEAM, OR FETAL CHARACTERISTICS.

PATIENTS WILL BE DIVIDED INTO TWO GROUPS:

  • GROUP 1:** PREGNANT WOMEN DIAGNOSED WITH GESTATIONAL DIABETES MELLITUS (GDM)
  • GROUP 2:** PREGNANT WOMEN WITHOUT A DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS (GDM) DATA REGARDING THE PATIENTS INCLUDED IN THE STUDY WILL BE OBTAINED FROM PATIENT CHARTS, HOSPITAL INFORMATION MANAGEMENT SYSTEM (HIMS) RECORDS, AND ULTRASONOGRAPHIC MEASUREMENTS PERFORMED BY THE RESEARCHER DURING THE PREOPERATIVE PERIOD. ALL DATA WILL BE PROSPECTIVELY RECORDED ON A STANDARDIZED CASE REPORT FORM.

**DATA TO BE COLLECTED:**

  • DEMOGRAPHIC DATA:** AGE, BODY MASS INDEX (BMI), GESTATIONAL AGE
  • CLINICAL DATA:** PRESENCE OF GESTATIONAL DIABETES MELLITUS (GDM), ASA PHYSICAL STATUS CLASSIFICATION, FASTING DURATIONS (SEPARATELY FOR SOLIDS AND LIQUIDS, IN HOURS), AND COMORBIDITIES
  • ULTRASONOGRAPHIC MEASUREMENTS:** ANTEROPOSTERIOR (AP) DIAMETER OF THE GASTRIC ANTRUM, CRANIOCAUDAL (CC) DIAMETER, ANTRAL CROSS-SECTIONAL AREA (CSA), AND ESTIMATED GASTRIC VOLUME (ML) DURING THE PREOPERATIVE PERIOD, THE GASTRIC ANTRUM WILL BE ASSESSED USING AN ULTRASOUND DEVICE BY AN EXPERIENCED ANESTHESIA RESIDENT OR ANESTHESIOLOGIST. THE PATIENT WILL BE EXAMINED IN BOTH THE SUPINE AND RIGHT LATERAL DECUBITUS POSITIONS. THE ANTEROPOSTERIOR AND CRANIOCAUDAL DIAMETERS OF THE GASTRIC ANTRUM WILL BE MEASURED, AND THE ANTRAL CROSS-SECTIONAL AREA WILL BE CALCULATED.

FOR PATIENTS ENROLLED IN THE STUDY, TRANSABDOMINAL GASTRIC ULTRASOUND WILL BE PERFORMED TWICE, IN TWO DIFFERENT POSITIONS, DURING THE PREOPERATIVE PERIOD. NO INTERVENTIONS WILL BE MADE REGARDING THE PLANNED MEDICAL TREATMENT OR SURGICAL PROCEDURE. ONLY NON-INVASIVE ROUTINE MEDICAL MEASUREMENTS WILL BE PERFORMED TO ASSESS THE PATIENT'S CURRENT CLINICAL STATUS.

Tipo de estudio

De observación

Inscripción (Estimado)

54

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Mehmet Tunç
  • Número de teléfono: +90 542 373 6350
  • Correo electrónico: otuncoo@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Método de muestreo

Muestra de probabilidad

Población de estudio

PREGNANT WOMEN AGED 18-65 YEARS WITH A SINGLETON PREGNANCY, GESTATIONAL AGE OF 36 WEEKS OR MORE.

Descripción

Inclusion Criteria:

  • PREGNANT WOMEN AGED 18-65 YEARS WITH A SINGLETON PREGNANCY,
  • GESTATIONAL AGE OF 36 WEEKS OR MORE,
  • ASA PHYSICAL STATUS CLASSIFICATION OF II-III WILL BE INCLUDED IN THE STUDY.
  • PARTICIPANTS WILL BE SELECTED FROM PATIENTS SCHEDULED FOR ELECTIVE CESAREAN SECTION WHO HAVE BEEN INFORMED ABOUT THE OBJECTIVES AND PROCEDURES OF THE STUDY AND WHO SIGN THE INFORMED CONSENT FORM.

Exclusion Criteria:

  • EMERGENCY CESAREAN SECTION CASES.
  • MULTIPLE PREGNANCIES.
  • PATIENTS WITH GASTROINTESTINAL DISEASES, INCLUDING SYMPTOMATIC OR TREATMENT-REQUIRING GASTROESOPHAGEAL REFLUX DISEASE, PEPTIC ULCER DISEASE, ACTIVE SYMPTOMATIC GASTRITIS, A HISTORY OF DIABETIC GASTROPARESIS, INFLAMMATORY BOWEL DISEASES (CROHN'S DISEASE OR ULCERATIVE COLITIS), OR A HISTORY OF GASTROINTESTINAL SURGERY, PARTICULARLY GASTRIC OR ESOPHAGEAL SURGERY.
  • PATIENTS WITH SYSTEMIC DISEASES THAT MAY AFFECT GASTRIC MOTILITY, INCLUDING TYPE 1 OR TYPE 2 DIABETES MELLITUS (EXCLUDING GDM), UNCONTROLLED HYPOTHYROIDISM OR HYPERTHYROIDISM, NEUROLOGICAL DISEASES (E.G., PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, OR AUTONOMIC NEUROPATHY), OR CONNECTIVE TISSUE DISEASES (E.G., SCLERODERMA).
  • PATIENTS WITH SEVERE SYSTEMIC COMORBIDITIES, INCLUDING ASA PHYSICAL STATUS CLASSIFICATION IV OR HIGHER, ADVANCED CARDIAC DISEASE (E.G., NYHA CLASS III-IV HEART FAILURE), ADVANCED RESPIRATORY SYSTEM DISEASE (E.G., SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE OR RESTRICTIVE LUNG DISEASE), RENAL FAILURE (STAGE 4-5 CHRONIC KIDNEY DISEASE), OR HEPATIC FAILURE (CHILD-PUGH CLASS B-C).
  • PATIENTS USING MEDICATIONS THAT MAY AFFECT GASTRIC MOTILITY, INCLUDING PROKINETIC AGENTS, ANTICHOLINERGIC DRUGS, OR OPIOIDS.
  • PATIENTS WHO REFUSE TO PARTICIPATE IN THE STUDY OR DO NOT SIGN THE INFORMED CONSENT FORM.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
GDM Group
Pregnant women with a confirmed diagnosis of gestational diabetes mellitus (per IADPSG/Carpenter-Coustan criteria) at ≥24 weeks of gestation, undergoing bedside gastric ultrasonography.
Bedside gastric ultrasound performed with a curvilinear probe in the supine and right lateral decubitus positions. The antrum is imaged in a sagittal plane at the level of the aorta; antral cross-sectional area (CSA) is measured and gastric volume is estimated using the Perlas model. Qualitative antral grading (Grade 0-2) is also recorded.
Non-GDM Group
Pregnant women without gestational diabetes, matched for gestational age and fasting duration, undergoing the same gastric ultrasonography protocol
Bedside gastric ultrasound performed with a curvilinear probe in the supine and right lateral decubitus positions. The antrum is imaged in a sagittal plane at the level of the aorta; antral cross-sectional area (CSA) is measured and gastric volume is estimated using the Perlas model. Qualitative antral grading (Grade 0-2) is also recorded.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
THE PRIMARY OBJECTIVE OF THIS STUDY IS TO COMPARE GASTRIC VOLUME PRIOR TO ELECTIVE CESAREAN SECTION BETWEEN PREGNANT WOMEN DIAGNOSED WITH GESTATIONAL DIABETES MELLITUS (GDM) AND THOSE WITHOUT GDM.
Periodo de tiempo: 1 YEAR
1 YEAR

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de octubre de 2026

Finalización primaria (Estimado)

1 de septiembre de 2027

Finalización del estudio (Estimado)

1 de octubre de 2027

Fechas de registro del estudio

Enviado por primera vez

8 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

8 de septiembre de 2026

Publicado por primera vez (Actual)

14 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

14 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

8 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir